Greater collaboration between scientists from multiple disciplines can give your drug discovery projects a greater chance of success. But how? In our eBook, you'll learn how an integrated approach can help reduce your risk of failure. Download now.
Biogen has been in hot water lately thanks to the contentious FDA approval of Alzheimer’s disease therapy Aduhelm based on a debatable biomarker. Now, the Big Biotech has turned in data on another biomarker plus an analysis the company says suggests association with a slowing of disease progression.
For emerging companies seeking to expand into Europe, there are many complexities and potential pitfalls. This 77-page e-book outlines the 7 keys to success when entering Europe for the first time. Download now.
The rat-a-tat-tat pace of dealmaking at Merck spinout Organon continues. Having identified more than 140 clinical-phase assets in its wheelhouse, Organon has pulled the trigger on its third deal in six months by agreeing to buy Forendo Pharma for an initial $75 million.
In a complaint filed Nov. 10, states argued that the Biden administration's healthcare worker vaccine requirements will exacerbate the ongoing labor shortage, particularly in rural areas.
After medtech peers like Medtronic and BD pledged to work toward net-zero carbon emissions and carbon neutrality in the coming decades, Siemens Healthineers is jumping on the carbon-neutral train.
Are seaweed-controlled oral cell therapies the future of inflammatory bowel disease therapy? That is the question posed by the latest deal from Genentech, which is teaming up with Novome Biotechnologies to study a novel approach to the indication.
Prexasertib has been investigated in nearly 20 clinical studies since being discovered by Array in the 1990's, but Eli Lilly decided to part ways with it in 2019. Now, Acrivon Therapeutics has $100 million in funding to give the drug another shot at potentially treating solid cancers through an equity and licensing agreement with Lilly.
With its recently bestowed breakthrough device designation positioning Viome Life Sciences’ mRNA analysis platform firmly in the FDA’s good graces, the gut-testing company has raised $54 million to continue developing the platform.
To treat a persistent arrhythmia, surgeons need a map of the cardiac muscle’s electrical activity, a process that takes several, often invasive steps. Vektor Medical's system can help clinicians chart out arrhythmia hotspots noninvasively in 2D and 3D diagrams in less than three minutes.
Members in most Blue Cross NC's individual and fully insured group plans will be able to access Teladoc Health's virtual platform for acute care and behavioral healthcare needs, the company said.
Through its Carbon Health Connect program, the company will establish technologic and operational integrations with vetted health systems and specialty care providers with the end goal of low-friction patient referrals. The primary care chain has already named John Muir Health as its inaugural partner for the Bay Area.
